(EMAILWIRE.COM, September 14, 2017 ) The report "Contrast Media/Contrast Agent Market by Type (Iodinated, Gadolinium, Barium, & Microbubble), Procedure (X-Ray/CT, MRI, & Ultrasound) & Application (Radiology, Interventional Radiology, & Interventional Cardiology) - Global Forecasts to 2021", analyzes and studies the major market drivers, restraints/challenges, and opportunities.

Browse 77 market data tables and 41 figures spread through 159 pages and in-depth TOC on “Contrast Media/Contrast Agent Market by Type (Iodinated, Gadolinium, Barium, & Microbubble), Procedure (X-Ray/CT, MRI, & Ultrasound) & Application (Radiology, Interventional Radiology, & Interventional Cardiology) - Global Forecasts to 2021”

Early buyers will receive 10% customization on reports.

The global contrast media/contrast agents market has been segmented on the basis of type, route of administration, indication, procedure, application, and region.

Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=911

Based on type, the contrast media/contrast agents market is segmented into iodinated contrast media, gadolinium-based contrast media, barium-based contrast media, and microbubble contrast media. In 2016, the iodinated contrast media segment is estimated to account for the largest share of the contrast media/contrast agents market, by type. However, the microbubble contrast media segment is expected to grow at the highest CAGR during the forecast period. The high growth of the microbubble segment can be attributed to the large number of on-going academic researches that are exploring various attributes of microbubbles in off-label indications for diagnosis as well as drug delivery.

Based on procedure, the contrast media/contrast agents market is segmented into X-ray/computed tomography, magnetic resonance imaging, and ultrasound.

Get Free Report Sample Pages: http://www.marketsandmarkets.com/requestsample.asp?id=911

Based on route of administration, the contrast media/contrast agents market has been segmented into oral, injectable, rectal, and urethral routes. In 2016, the injectable segment is expected to account for the largest share of the contrast media/contrast agents market. Growth in the injectable contrast media segment can be attributed to advancements in CT and MRI imaging technologies, which majorly use injectable contrast media.

Based on indication, the contrast media/contrast agents market is segmented into cardiovascular disorders, oncology, gastrointestinal disorders, musculoskeletal disorders, neurological disorders, and nephrological disorders. In 2016, the cardiovascular disorders segment is estimated to account for the largest share of the global contrast media/contrast agents market. Improvements in cardiac MRI procedures in cath labs, favorable reimbursement policies for contrast media used in cardiovascular diagnosis, and strong healthcare infrastructure in countries like the U.S., Canada, the U.K., and Germany are some of the factors driving the growth of this segment.

Based on procedure, the global contrast media/contrast agents market is segmented into X-ray/CT, MRI, and ultrasound. In 2016, the X-ray/CT segment is expected to account for the largest share of the contrast media/contrast agents market. However, the ultrasound segment is expected to register the highest CAGR during the forecast period. Development of microbubble contrast media for ultrasound, and large number of approvals for ultrasound contrast media in major markets such as the U.S., Europe, and Japan are some of the key factors driving the growth of this segment.

Based on application, the global contrast media/contrast agents market has been segmented into radiology, interventional radiology, and interventional cardiology. In 2016, the radiology segment is estimated to account for the largest share of the contrast media/contrast agents market. The large share of this segment can be attributed to the growing number of diagnostic procedures/centers, coupled with the increasing disease burden on countries.

The prominent players in the global contrast media/contrast agents market include Bayer HealthCare (Germany), GE Healthcare (U.S.), Guerbet Group (France), and Bracco Imaging S.p.A. (Italy). These companies hold a dominant position in the contrast media/contrast agents market mainly due to their well-established presence in the field of genomics, presence in over 50 countries, high R&D investments, and strong sales and distribution force. Other players operating in this market include Lantheus Medical Imaging (U.S.), nanoPET Pharma GmbH (Germany), CMC Contrast AB (Sweden), Daiichi Sankyo (Japan), and Subhra Pharma Private Limited (India).